Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1356455

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has received a request from the Scottish Government to discuss the impact on Scotland of the UK Government's notice of termination of the COVID-19 Vaccine Supply Agreement with Valneva.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51029
	answer	answer is ministerial correction date of answer 22/09/2021 answer text <p>Ministers regularly discuss COVID-19 vaccine matters with the Scottish Government and other devolved administrations.</p><p> </p><p>My Rt. Hon. Friend the Secretary of State for Health has discussed the termination of our supply agreement with Valneva with his counterpart in the Scottish Government and the UK Government will maintain dialogue with the Scottish Government on this matter.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 51033 51034 question first answered 22/09/2021 16:39:07 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey

1356456

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what discussions (a) he and (b) Ministers in his Department have had with the Scottish Government (i) prior to and (b) since the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva, on that matter.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51030
	answer	answer is ministerial correction date of answer 27/09/2021 answer text <p>Ministers regularly discuss COVID-19 vaccine matters with the Scottish Government and other devolved administrations.</p><p> </p><p>My Rt. Hon. Friend the Secretary of State for Health has discussed the termination of our supply agreement with Valneva with his counterpart in the Scottish Government and the UK Government will maintain dialogue with the Scottish Government on this matter.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/09/2021 15:18:32 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey

1356457

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the impact of the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva on his Department’s ability to meet vaccine supply requirements.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51031
	answer	answer is ministerial correction date of answer 27/09/2021 answer text <p>Our vaccination programme is continuing to make phenomenal progress, with four out of every five adults now fully vaccinated against COVID-19.</p><p> </p><p>I cannot comment on commercial decisions, the termination of our supply agreement with Valneva will have no impact on our vaccine supplies for autumn.</p><p> </p><p>The UK has contracted for a portfolio of vaccines from a number of developers, and we have sufficient contracted supply for the expected booster campaign as well as to complete the first round of vaccinations.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 51032 question first answered 27/09/2021 15:13:43 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey

1356458

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what contingency measures the Government has put in place to ensure adequacy of covid-19 vaccine supply in response to the Government's notice of termination of the covid-19 vaccine supply agreement with Valneva.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51032
	answer	answer is ministerial correction date of answer 27/09/2021 answer text <p>Our vaccination programme is continuing to make phenomenal progress, with four out of every five adults now fully vaccinated against COVID-19.</p><p> </p><p>I cannot comment on commercial decisions, the termination of our supply agreement with Valneva will have no impact on our vaccine supplies for autumn.</p><p> </p><p>The UK has contracted for a portfolio of vaccines from a number of developers, and we have sufficient contracted supply for the expected booster campaign as well as to complete the first round of vaccinations.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 51031 question first answered 27/09/2021 15:13:43 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey

1356459

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Valneva: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has received a request from the Scottish Government to discuss the impact of the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51033
	answer	answer is ministerial correction date of answer 22/09/2021 answer text <p>Ministers regularly discuss COVID-19 vaccine matters with the Scottish Government and other devolved administrations.</p><p> </p><p>My Rt. Hon. Friend the Secretary of State for Health has discussed the termination of our supply agreement with Valneva with his counterpart in the Scottish Government and the UK Government will maintain dialogue with the Scottish Government on this matter.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 51029 51034 question first answered 22/09/2021 16:39:07 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey

1356460

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Valneva: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what discussions (a) he and (b) Ministers in his Department have had with the Scottish Government since the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva was issued, on that matter.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51034
	answer	answer is ministerial correction date of answer 22/09/2021 answer text <p>Ministers regularly discuss COVID-19 vaccine matters with the Scottish Government and other devolved administrations.</p><p> </p><p>My Rt. Hon. Friend the Secretary of State for Health has discussed the termination of our supply agreement with Valneva with his counterpart in the Scottish Government and the UK Government will maintain dialogue with the Scottish Government on this matter.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 51029 51033 question first answered 22/09/2021 16:39:07 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey

1356461

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Valneva: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the impact of the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva on (a) vaccine provision and (b) science, research and innovation in the UK.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51035
	answer	answer is ministerial correction date of answer 22/09/2021 answer text <p>The UK has contracted for a portfolio of vaccines from a number of developers, and we have sufficient contracted supply for the expected booster campaign as well as to complete the first round of vaccinations.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/09/2021 16:59:47 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey

1356462

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Valneva: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to ensure diversity of (a) suppliers and (b) technology within vaccine provision in the context of the notice of termination of the covid-19 vaccine supply agreement with Valneva.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51036
	answer	answer is ministerial correction date of answer 27/09/2021 answer text <p>The Government’s approach to seeking a vaccine for COVID-19 has, from the outset, been to secure access to a portfolio of candidate vaccines from a range of developers. This has resulted in four regulated COVID-19 vaccines within the portfolio to date providing both diversity of supply and diversity of vaccine type.</p><p> </p><p>The Government has secured early access to 332 million COVID-19 vaccines doses through supply agreements with five separate vaccine developers. This includes agreements with:</p><p> </p><ul><li>Pfizer/BioNTech for 135 million doses of its mRNA vaccine;</li><li>University of Oxford/AstraZeneca for 100 million doses of its adenovirus vaccine;</li><li>Moderna for 17 million doses of its mRNA vaccine;</li><li>Novavax for 60 million doses of its protein adjuvant vaccine; and</li><li>Janssen for 20 million doses of its adenovirus vaccine.</li></ul><p>Of these COVID-19 vaccines, the AstraZeneca vaccine is manufactured in the UK and Novavax has a UK supply chain subject to regulatory approval. Vaccine manufacture is a global business, and the response to COVID-19 a global effort, and we are proud of AstraZeneca’s contribution to that from the UK.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 51037 question first answered 27/09/2021 15:16:24 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey

1356463

	registered interest
	date	17/09/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Vaccination: Manufacturing Industries
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, if he will list those companies manufacturing vaccines or developing vaccines in the UK which use (a) messenger RNA and (b) inactivated virus.
	tabling member constituency	Kirkcaldy and Cowdenbeath
	tabling member printed	Neale Hanvey
	uin	51037
	answer	answer is ministerial correction date of answer 27/09/2021 answer text <p>The Government’s approach to seeking a vaccine for COVID-19 has, from the outset, been to secure access to a portfolio of candidate vaccines from a range of developers. This has resulted in four regulated COVID-19 vaccines within the portfolio to date providing both diversity of supply and diversity of vaccine type.</p><p> </p><p>The Government has secured early access to 332 million COVID-19 vaccines doses through supply agreements with five separate vaccine developers. This includes agreements with:</p><p> </p><ul><li>Pfizer/BioNTech for 135 million doses of its mRNA vaccine;</li><li>University of Oxford/AstraZeneca for 100 million doses of its adenovirus vaccine;</li><li>Moderna for 17 million doses of its mRNA vaccine;</li><li>Novavax for 60 million doses of its protein adjuvant vaccine; and</li><li>Janssen for 20 million doses of its adenovirus vaccine.</li></ul><p>Of these COVID-19 vaccines, the AstraZeneca vaccine is manufactured in the UK and Novavax has a UK supply chain subject to regulatory approval. Vaccine manufacture is a global business, and the response to COVID-19 a global effort, and we are proud of AstraZeneca’s contribution to that from the UK.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 51036 question first answered 27/09/2021 15:16:24 answering member 4020 label Biography information for George Freeman
	tabling member	4782 label Biography information for Neale Hanvey